1-5 of 5
Rod Humerickhouse, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies

Sathej Gopalakrishnan, PhD, Brenda Chyla, PhD, Sven Mensing, PhD, Rajeev Menon, PhD, Rod Humerickhouse, MD PhD, Walid Awni, PhD, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4318.
https://doi.org/10.1182/blood.V130.Suppl_1.4318.4318
Published: 2017
Journal Articles

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

John F Seymour, MBBS, PhD, Thomas J. Kipps, MD, Barbara F. Eichhorst, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, James M. D'Rozario, MBBS FRACP FRCPA, Sarit Assouline, MD, Carolyn Jane Owen, MD FRCPC, John Gerecitano, MD PhD, Tadeusz Robak, MD PhD, Javier De la Serna, MD, Ulrich Jaeger, MD, Guillaume Cartron, MD PhD, Marco Montillo, MD, Rod Humerickhouse, MD PhD, Elizabeth Punnoose, PhD, Yan Li, PhD, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Mehrdad Mobasher, MD, MPH, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-2.LBA-2
Published: 2017
Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2374.
https://doi.org/10.1182/blood.V114.22.2374.2374
Published: 2009
Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD
Journal: Blood
Blood (2008) 112 (11): 4008.
https://doi.org/10.1182/blood.V112.11.4008.4008
Published: 2008
Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3177.
https://doi.org/10.1182/blood.V112.11.3177.3177
Published: 2008